For example Kynamro, a second-generation 2 ́ methoxyethyl ASO targeting human apoB, has been approved by the FDA for use as an adjunct with first-line therapies to reduce apoB and total cholesterol in homozygous familial hypercholesterolemia (FH) patients. This evidence concerns the gene APOB and familial hypercholesterolemia.